文献速递肝病

Golexanolone治疗隐匿性肝性脑病的初步研究

A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy.
PubMed 文献 · J Hepatol · 2021-04-21

Golexanolone是一种新型GABA-A受体调节类固醇拮抗剂,在肝硬化伴隐匿性肝性脑病患者中进行了随机、安慰剂对照的初步研究,评估其安全性、药代动力学和疗效。结果显示药物耐受性良好,在Epworth嗜睡量表(ESS)和脑电图DT/AB比值方面较安慰剂有方向性改善,认知测试未见组间统计学差异,但事后分析提示认知获益信号。

要点

  • Golexanolone在肝硬化伴隐匿性肝性脑病患者中安全性和药代动力学良好。
  • 预设分析显示ESS(p=0.047)和DT/AB(p=0.021)较安慰剂有方向性改善。
  • 认知测试(CRT、PHES、ANT)无组间统计学差异,但事后分析提示获益信号。

核心结论

  • Golexanolone耐受性良好,并与认知表现改善相关,提示GABA-A受体调节神经类固醇参与肝性脑病发病机制。

研究设计与样本

  • 单次/多次递增剂量研究后,Child-Pugh A/B级肝硬化且筛查时连续反应时间(CRT)异常成人随机接受3周golexanolone(10、40或80 mg BID)或安慰剂。
  • 安慰剂组12例,golexanolone组33例。

主要发现

  • 预设分析显示golexanolone较安慰剂在ESS(p=0.047)、MDF(p=0.142)和DT/AB(p=0.021)呈方向性有利变化。
  • 所有患者在CRT、PHES和ANT均呈方向性有利变化,但golexanolone与安慰剂间无统计学差异。
  • 事后分析考虑筛查至基线期间CRT、PHES和ANT的变异与改善,提示认知指标也存在疗效信号。

关键数值与推荐

  • Golexanolone剂量为10、40或80 mg每日两次,疗程3周。
  • 预设分析中ESS的p=0.047,DT/AB的p=0.021,MDF的p=0.142。

临床怎么用

  • 对于肝硬化伴隐匿性肝性脑病患者,golexanolone可能改善嗜睡和脑电图指标,但认知测试获益需进一步验证。
  • 目前证据来自初步研究,尚不能支持常规临床使用。

局限性

  • 样本量较小(安慰剂12例,golexanolone 33例)。
  • 认知测试主要终点未达统计学差异,部分结果为事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Golexanolone is a novel small molecule GABA-A receptor-modulating steroid antagonist under development for the treatment of cognitive and vigilance disorders caused by allosteric over-activation of GABA-A receptors by neurosteroids. It restored spatial learning and motor coordination in animal models of hepatic encephalopathy (HE) and mitigated the effects of intravenous allopregnanolone in healthy adults in a dose-dependent fashion. Herein, we report data on the safety, pharmacokinetics (PK) and efficacy of golexanolone in adult patients with cirrhosis. METHODS: Following single/multiple ascending dose studies, adults with Child-Pugh A/B cirrhosis and abnormal continuous reaction time (CRT) on screening were randomized to 3 weeks' dosing with golexanolone (10, 40 or 80 mg BID) or placebo. CRT, psychometric hepatic encephalopathy score (PHES), animal naming test (ANT), Epworth sleepiness scale (ESS) and electroencephalogram (mean dominant frequency [MDF]; delta+theta/alpha+beta ratio [DT/AB]) were obtained at baseline, 10, and 21 days. RESULTS: Golexanolone exhibited satisfactory safety and PK. Baseline characteristics were similar between the 12 and 33 patients randomized to placebo or golexanolone, respectively. By prespecified analyses, golexanolone was associated with directionally favourable changes vs. placebo in ESS (p = 0.047), MDF (p = 0.142) and DT/AB (p = 0.021). All patients also showed directionally favourable changes in CRT, PHES and ANT, but with no statistical difference between golexanolone and placebo. Post hoc analyses taking into account the variability and improvement in CRT, PHES and ANT observed between screening and baseline suggested an efficacy signal by cognitive measures as well. CONCLUSION: Golexanolone was well tolerated and associated with improvement in cognitive performance. These results implicate GABA-A receptor-modulating neurosteroids in the pathogenesis of HE and support the therapeutic potential of golexanolone. LAY SUMMARY: Many patients with cirrhosis experience subtle but disabling cognitive problems, including sleepiness and poor attention span, that impair their ability to be gainfully employed or carry out activities of daily living. This pilot study tested the hypothesis that these problems with cognition, for which there is no approved treatment, might be improved by an experimental drug, golexanolone, designed to normalize the function of receptors which inhibit brain function. The results of this study suggest that golexanolone is well tolerated and may improve cognition, as reflected by measures of sleepiness, attention span and brain wave activity, paving the way for future larger studies of this promising experimental drug. CLINICAL TRIAL REGISTRATION NUMBER: EudraCT 2016-003651-30.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Montagnese S, Lauridsen M, Vilstrup H, et al. A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy. J Hepatol. 2021. PMID: 33894327. doi:10.1016/j.jhep.2021.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。